Pfizer announced in February 2025 that it was taking Beqvez (fidanacogene elaparvovec), its gene therapy for hemophilia B, ...
CAR-T cell therapy has spread into earlier lines of care over the last ten years, going beyond heavily pretreated populations ...
Pfizer and BioMarin have pulled their hemophilia gene therapies, citing low demand. To prepare for his presentation at the ...
In 2024, the number of uninsured people in the United States rose for the first time since 2019, according to a recently ...
Patient adoption remains high. Data show that about 8.6 million patients used GLP-1 drugs for diabetes over a one-year period ...
The diagnostic criteria for narcolepsy type 1 have undergone some changes within the last few years, and it is important that ...
In 'Breaking Down the 2026 ADA CGM Guidelines,' our panel of experts delve into the following critical question: 1. What are ...
World Experiences Switching Patients to CGM Devices,' the experts explore the following question: 1. What is a patient case ...
The first biosimilars referencing Humira became available in 2023. That year, 10 FDA-approved adalimumab are now on the ...
Programs such as copay accumulators, maximizers, and other alternative funding programs may provide short-term savings but ...
On the data side, tools now exist that integrate both medical and pharmacy claims into a holistic picture. An example is the ...
At the AMCP Annual Meeting, experts from Prime Therapeutics said education, policy alignment and collaboration can help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results